3-hydroxyisothiazole-4-carboxamidine derivatives as CHK2 inhibitors
View Patent ↗This invention provides compounds of Formula I which are inhibitors of Chk2 and are useful as a radiation protection agents in anticancer radiotherapy. A method of modulating Chk2 in vitro includes treating a substrate with Chk2 in the presence of compounds of formula I. A method of making a compound of formula I includes: a) forming a biaryl amine having an amino (NH 2 ) group; b) converting the amino group to an isothiocyanate group; c) adding a cyanoacetamide to the isothiocyanate group to form a thioamide adduct; d) cyclizing the thioamide adduct to form an isothiazole having a cyano group; and e) adding an amine to the cyano group to form a carboxamidine group.
1. A compound of formula III:
wherein
R 1 is OH; O—C 1 -C 6 alkyl; C 1 -C 6 alkyl, said C 1 -C 6 alkyl groups optionally substituted with one to three groups selected independently from hydroxy, halogen, C 1 -C 3 alkoxy, and phenyl; or R 1 is —CH 2 B or —CH 2 CH 2 B, where B is selected from C 3-7 cycloalkyl, C 7 -C 9 bicycloalkyl, pyridyl, piperazinyl, piperidinyl, N-morpholyl, tetrahydrofuryl, and naphthyl; C 3 -C 7 cycloalkyl; C 7 -C 9 bicycloalkyl, where all cycloalkyl, bicycloalkyl, pyridyl, piperazinyl, piperidinyl, N-morpholyl, tetrahydrofuryl, and naphthyl groups are optionally substituted with one to three groups selected independently from hydroxy, halogen, and methyl;
or R 1 is (CH 2 ) n -G, where n is 1 or 2 and G is a five- or six-membered ring or a 9-14-membered fused ring system, wherein each ring optionally contains 1-3 heteroatoms selected independently from O, N, and S; wherein each ring is optionally substituted with 1-3 groups selected independently from the following: halogen, hydroxy, cyano, oxo, and C 1 -C 4 alkyl, wherein said C 1 -C 4 alkyl group is optionally substituted with one to three halogen atoms; and wherein each ring optionally contains one or more double bonds;
or R 1 is —CH(CH 2 OH)CH 2 D, where D is selected from imidazolyl, indolyl, carboxamido, phenyl, cyclohexyl, —CH 2 SCH 3 , and adamantin-1-yl;
R 2 and R 3 vary independently and are selected from the group consisting of hydrogen; halogen; hydroxy; nitro; cyano; C 1 -C 4 alkyl; OC 1 -C 4 alkyl, where the C 1 -C 4 alkyl groups and the C 1 -C 4 alkyl moieties of the OC 1 -C 4 alkyl groups are optionally substituted with one to three fluorine atoms; NR 6 R 7 , (CH 3 ) 2 N; CH 3 OC(O); CH 3 CH 2 OC(O); —C(O)NR 6 R 7 ; or —S(O) 2 NR 6 R 7 , where R 6 and R 7 are, independently, H, CH 3 , or CH 3 CH 2 ; or R 2 and R 3 are attached to adjacent carbons and, together with the ring atoms to which they are attached, form an additional, fused, five- or six-membered ring, optionally containing one heteroatom, which ring may be aromatic or aliphatic;
R 4 and R 5 vary independently and are selected from the group consisting of H, F, Cl, Br, CH 3 , or CF 3 ; and
salts thereof.
2. A compound of formula IV:
wherein
R 1 is OH; O—C 1 -C 6 alkyl; C 1 -C 6 alkyl, said C 1 -C 6 alkyl groups optionally substituted with one to three groups selected independently from hydroxy, halogen, C 1 -C 3 alkoxy, and phenyl; or R 1 is —CH 2 B or —CH 2 CH 2 B, where B is selected from C 3-7 cycloalkyl, C 7 -C 9 bicycloalkyl, pyridyl, piperazinyl, piperidinyl, N-morpholyl, tetrahydrofuryl, and naphthyl; C 3 -C 7 cycloalkyl; C 7 -C 9 bicycloalkyl, where all cycloalkyl, bicycloalkyl, pyridyl, piperazinyl, piperidinyl, N-morpholyl, tetrahydrofuryl, and naphthyl groups are optionally substituted with one to three groups selected independently from hydroxy, halogen, and methyl;
or R 1 is (CH 2 ) n -G, where n is 1 or 2 and G is a five- or six-membered ring or a 9-14-membered fused ring system, wherein each ring optionally contains 1-3 heteroatoms selected independently from O, N, and S; wherein each ring is optionally substituted with 1-3 groups selected independently from the following: halogen, hydroxy, cyano, oxo, and C 1 -C 4 alkyl, wherein said C 1 -C 4 alkyl group is optionally substituted with one to three halogen atoms; and wherein each ring optionally contains one or more double bonds;
or R 1 is —CH(CH 2 OH)CH 2 D, where D is selected from imidazolyl, indolyl, carboxamido, phenyl, cyclohexyl, —CH 2 SCH 3 , and adamantin-1-yl;
R 2 is selected from the group consisting of hydrogen or halogen; and
and salts thereof.
3. The compound of any one of claim 1 or 2 , wherein R 1 is C 1 -C 6 alkyl, optionally substituted with one or two OH groups.
4. The compound of any one of claim 1 or 2 , wherein R 1 is —CH 2 B, where B is selected from a C 3-7 cycloalkyl.
5. The compound of any one of claim 1 or 2 , wherein or R 1 is —CH 2 B or —CH 2 CH 2 B, where B is naphthyl.
6. The compound of any one of claim 1 or 2 , wherein R 2 is hydrogen or bromine.
7. A compound selected from the group consisting of compounds:
8. A method of inhibiting Chk2 in vitro comprising treating a substrate with Chk2 in the presence of a compound according to any one of claim 1 or 2 .
9. A method of making a compound of any one of claim 1 or 2 comprising:
a) forming a biaryl amine having an amino (NH 2 ) group;
b) converting the amino group to an isothiocyanate group;
c) adding a cyanoacetamide to said isothiocyanate group to form a thioamide adduct;
d) cyclizing said thioamide adduct to form an isothiazole having a cyano group; and
e) adding an amine to said cyano group to form a carboxamidine group.